首页> 美国卫生研究院文献>Drug Metabolism and Disposition >Heterotropic Activation of the Midazolam Hydroxylase Activity of CYP3A by a Positive Allosteric Modulator of mGlu5: In Vitro to In Vivo Translation and Potential Impact on Clinically Relevant Drug-Drug Interactions
【2h】

Heterotropic Activation of the Midazolam Hydroxylase Activity of CYP3A by a Positive Allosteric Modulator of mGlu5: In Vitro to In Vivo Translation and Potential Impact on Clinically Relevant Drug-Drug Interactions

机译:CYP3A的Midazolam羟化酶活性通过mGlu5的正变构调节剂的异向活化:体内到体内翻译及其对临床相关药物相互作用的潜在影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Allosteric modulation of G protein-coupled receptors has gained considerable attention in the drug discovery arena because it opens avenues to achieve greater selectivity over orthosteric ligands. We recently identified a series of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 5 (mGlu5) for the treatment of schizophrenia that exhibited robust heterotropic activation of CYP3A4 enzymatic activity. The prototypical compound from this series, 5-(4-fluorobenzyl)-2-((3-fluorophenoxy)methyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (VU0448187), was found to activate CYP3A4 to >100% of its baseline intrinsic midazolam (MDZ) hydroxylase activity in vitro; activation was CYP3A substrate specific and mGlu5 PAM dependent. Additional studies revealed the concentration-dependence of CYP3A activation by VU0448187 in multispecies hepatic and intestinal microsomes and hepatocytes, as well as a diminished effect observed in the presence of ketoconazole. Kinetic analyses of the effect of VU0448187 on MDZ metabolism in recombinant P450 or human liver microsomes resulted in a significant increase in Vmax (minimal change in Km) and required the presence of cytochrome b5. The atypical kinetics translated in vivo, as rats receiving an intraperitoneal administration of VU0448187 prior to MDZ treatment demonstrated a significant increase in circulating 1- and 4-hydroxy- midazolam (1-OH-MDZ, 4-OH-MDZ) levels compared with rats administered MDZ alone. The discovery of a potent substrate-selective activator of rodent CYP3A with an in vitro to in vivo translation serves to illuminate the impact of increasing intrinsic enzymatic activity of hepatic and extrahepatic CYP3A in rodents, and presents the basis to build models capable of framing the clinical relevance of substrate-dependent heterotropic activation.
机译:G蛋白偶联受体的变构调节已在药物开发领域引起了广泛关注,因为它为实现正构配体打开了更大的选择途径。我们最近确定了一系列代谢型谷氨酸受体5(mGlu5)的正变构调节剂(PAMs),用于治疗精神分裂症,表现出强大的CYP3A4酶活性的异质性激活。发现该系列的原型化合物5-(4-氟苄基)-2-((3-氟苯氧基)甲基)-4,5,6,7-四氢吡唑并[1,5-a]吡嗪(VU0448187)在体外激活CYP3A4使其基线固有咪达唑仑(MDZ)羟化酶活性> 100%;激活是CYP3A底物特异性和mGlu5 PAM依赖性的。其他研究显示,VU0448187在多种肝,肠微粒体和肝细胞中对CYP3A的激活具有浓度依赖性,并且在存在酮康唑的情况下,其作用减弱。动力学分析VU0448187对重组P450或人肝微粒体中MDZ代谢的影响,导致Vmax显着增加(Km的最小变化),并且需要存在细胞色素b5。非典型动力学在体内翻译,因为在大鼠接受MDZ治疗前腹膜内给予VU0448187的大鼠与大鼠相比,其循环1-和4-羟基咪达唑仑(1-OH-MDZ,4-OH-MDZ)水平显着增加单独管理MDZ。发现具有体外到体内翻译功能的啮齿动物CYP3A的有效底物选择性激活剂,旨在阐明啮齿动物中肝脏和肝外CYP3A内在酶活性增加的影响,并为建立能够构建临床模型的基础提供基础底物依赖性异向激活的相关性。

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号